Mustang Bio (NASDAQ:MBIO) Trading Up 3.8% – Should You Buy?

Mustang Bio, Inc. (NASDAQ:MBIO)’s stock price shot up 3.8% during mid-day trading on Monday . The company traded as high as $0.6540 and last traded at $0.6520. Approximately 13,912 shares traded hands during trading, a decline of 64% from the average daily volume of 38,956 shares. The stock had previously closed at $0.6282.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mustang Bio in a report on Friday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Mustang Bio Stock Performance

The stock has a market capitalization of $4.29 million, a P/E ratio of -1.18 and a beta of 2.05. The firm has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $0.81.

Mustang Bio (NASDAQ:MBIO) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($140.00) by $139.86.

Hedge Funds Weigh In On Mustang Bio

An institutional investor recently bought a new stake in Mustang Bio stock. DRW Securities LLC bought a new stake in shares of Mustang Bio, Inc. (NASDAQ:MBIO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned 1.01% of Mustang Bio at the end of the most recent quarter. Institutional investors own 9.95% of the company’s stock.

Mustang Bio Company Profile

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.